VRTHF: Why Pot Stock Profits Are On The Rise

You are receiving this third-party paid advertisement as an opt-in subscriber of Investors Alley.  This is not to be considered a recommendation or endorsement by Investors Alley Corp. or any of its affiliates.  Please see bottom of email for disclaimer and privacy policy. Click here to opt-out of receiving these emails.

A Perfect Storm... A Super-Hurricane of Booming Sales, Rapid Legalization, and Thunderous Acceptance of Legal Cannabis! "Veritas Pharma (OTC:VRTHF) is well positioned to identify and develop clinical cannabis derived treatments for a number of potential billion dollar markets." — Yahoo! Finance Dear Reader, It's hard to believe that in just five years, the U.S. has completely changed its views on cannabis. According to a 2015 Gallup poll, 58% of Americans support legalization of cannabis for adult use – up from just 36% ten years ago. U.S. legal cannabis sales will triple by 2020, and 86% of Americans already reside in a state that has legalized medical or recreational cannabis use. The compound annual growth rate of the legal U.S. cannabis industry is a staggering 30%. If you have missed the huge rallies in cannabis stocks during the past year, then you're in luck – Veritas Pharma (VRTHF) is just getting started. Veritas Pharma has a team of six, prestigious, world-renowned doctors who are hard at work in America's fastest-growing industry: legal cannabis. They are now investigating and patenting the cannabis cultivars that are best able to satisfy global demand. Patent-protected cannabis cultivars? That means new treatments for human health – that make a ton of money for VRTHF investors. Based in Vancouver, Canada – where cannabis is also legal – this company is staffed with an all-star team ready to change medicine as we know it. "Veritas takes a unique approach to the medicinal marijuana space with its innovative R&D strategy," says Guru Focus. "Virtual R&D is the hottest area of drug research today and Veritas is making good use of the technique," says Seeking Alpha. Yes, you read that correctly: Legal cannabis sales more than doubled since 2014 and will triple again by 2020. With growth like that... Is It Any Wonder That Cannabis Stocks Have Rallied 200% Or More This Year? Check out these actual results to see what type of potential Veritas Pharma (VRTHF) has. Cannabis stocks are some of the most explosive stocks in the world – they have rewarded their investors with quadruple-digit gains during 2016. GreenGro Technologies, Inc. rallied 1,100% within one month. American Green Inc. rallied 2,000% within three. Cannabis Science, Inc. rallied 1,500% within one month. Medical Marijuana, Inc. rallied 1,400% within one year. Totally Hemp Crazy Inc. rallied 3,100% within three months. Growlife, Inc. rallied 1,400% within one year. Cannabis Sativa, Inc. rallied 1,200% within one month. The Next Cannabis Stock To See A Massive Price Surge: Veritas Pharma (VRTHF) The bottom line is this: You need exposure to the fastest-growing billion dollar industry in the U.S. and Veritas Pharma (VRTHF) is positioned to become the next mega-winner in that industry: cannabis. I'll show you all the proof – including exactly why I believe this will be such a profitable investment for you – in this special report. Sincerely, Jeff Daniels Editor, The Stock Profiler P.S. Do you have a cannabis stock in your portfolio right now? It is America's fastest-growing billion dollar industry, period! Do yourself a favor and learn a bit about my favorite cannabis stock, Veritas Pharma (VRTHF).

 

 

 

If you enjoyed reading this email, click here to forward it to a friend or colleague.

You are receiving this message because you registered ignoble.experiment@arconati.us through INO.com Invite Sell - Apr 2014.
Click here to send us questions or comments regarding this mailing.  Opt-out using the link below.

This message from Investors Alley Corp. is being sent in full accordance with the CAN-SPAM Act.
We respect your privacy and, therefore, this email was sent directly from Investors Alley.  Please review our Privacy Statement and Terms of Use. 
If you no longer wish to receive emails from Investors Alley, please unsubscribe now.

Investors Alley Corp. makes no guarantee or warranty about what is advertised above. The opinions in this email and linked pages are not those of Investors Alley Corp. and are neither an offer nor a recommendation to buy or sell any security.  We have not independently verified the validity of the claims or statements contained in this email.  Investors Alley Corp. does not hold a position in the company covered in this email.  Investors Alley Corp. is not a registered investment firm nor a broker/dealer.  We urge you to always conduct your own research and due diligence and obtain professional advice before making any investment decision.  We will not be liable for any loss or damage caused by a reader's reliance on information obtained in this email or corresponding web sites.

All information contained herein is copyright 2016, Investors Alley Corp.
Investors Alley Corporation | 41 Madison Avenue | 31st Floor | New York, NY  10010

 

Update Your Profile Information | Modify Subscription Settings or Unsubscribe From Emails